Opendata, web and dolomites


Disruptive targeted drug delivery system via synergistic combination of intelligent DNA molecular machines and gated mesoporous nanoparticles

Total Cost €


EC-Contrib. €






 SMARTRIOX project word cloud

Explore the words cloud of the SMARTRIOX project. It provides you a very rough idea of what is the project "SMARTRIOX" about.

doxorubicin    course    roi    mainstay    progesterone    adjuvant    national    grow    aggressive    inside    bionanoparticle    molecular    shortened    dose    itself    yearly    suffering    nano    herceptin    turn    invested    cap    helpful    patients    resistant    bc    toxicities    bcs    cells    limit    render    oncologists    immune    tumour    anthracycline    setting    triox    economic    threshold    trioxnano    health    negative    women    primary    therapies    exclusively    shows    responding    date    ease    estrogen    547m    2021    although    orphan    free    diagnosis    receptors    potent    lacks    services    anticancer    company    15    diagnosed    concentrations    interval    epithelial    prevents    breast    achieves    metastatic    world    settings    recognizes    disease    mg2    profit    burden    tnbc    effectiveness    200    releases    cardiac    10    ttriple    machine    causes    positioning    primarily    accounts    maximal    atp    programmed    neoadjuvant    chemotherapy    cancer    levels    extremely    nonetheless    25    times    poor    digestive    lower    substantial    treatment    prognosis    dnazyme    market    17    txn770    endocrine    innovative    billion   

Project "SMARTRIOX" data sheet

The following table provides information about the project.


Organization address
address: ROKACH SHIMON 4
postcode: 9518705
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Israel [IL]
 Project website
 Total cost 2˙847˙667 €
 EC max contribution 1˙993˙367 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-06-01   to  2020-05-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    TRIOX NANO LTD IL (JERUSALEM) coordinator 1˙993˙367.00


 Project objective

Although there are tTriple Negative Breast Cancer (TNBC), the most aggressive type of Breast Cancer (BC), accounts for 15-25% of all BCs. Yearly 200,000 women are diagnosed with TNBC, of which 100,000 are diagnosed with metastatic disease at the primary diagnosis. TNBC lacks a recognized molecular target, making it an orphan disease: no effective treatment is available to date. The poor prognosis of patients suffering from TNBC makes it extremely challenging for both oncologists and patients. TNBC is more aggressive because all its receptors (Estrogen/Progesterone/Herceptin) are negative, and targeted and endocrine therapies are not helpful. TNBC shows a shortened disease-free interval in the neoadjuvant and adjuvant settings and a more aggressive course in the metastatic setting.The mainstay treatment for TNBC is Doxorubicin, a potent anthracycline chemotherapy, which nonetheless, has substantial toxicities (cardiac, immune, digestive and epithelial) that limit its maximal dose and render the tumour cells resistant to it. As a result, patients cannot be treated with a high enough and effective dose.In response, Triox Nano has developed TXN770: an innovative bionanoparticle based anticancer treatment. TXN770 has a DNAzyme machine cap that recognizes cancer cells and releases the chemotherapy exclusively inside them, responding to pre-programmed threshold levels of Mg2 and ATP that are present primarily at the target TNBC cells. This allows using 4 times lower concentrations of Doxorubicin, which in turn causes less side effects and achieves a higher effectiveness. It also prevents cancer cells from becoming resistant to Doxorubicin.TrioxNano will address a BC world market of $10.4 billion, expected to grow to $17.2 billion in 2021. TrioxNano projects €547M in profit, with a ROI of €15 per euro invested in the project and in turn will help ease the economic burden of TNBC in National Health Services while positioning itself as a leading company in treatment of TNBC.


List of deliverables.
Project Web page Websites, patent fillings, videos etc. 2020-01-14 14:23:12

Take a look to the deliverables list in detail:  detailed list of SMARTRIOX deliverables.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SMARTRIOX" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "SMARTRIOX" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More